Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study.
- Author:
Zeinab Mohamed Kamel ISMAIL
1
;
Noha Mohamed Afifi AMIN
;
Mira Farouk Youssef YACOUB
;
Amira Mohamed Osman MOHAMED
Author Information
1. Department of Histology, Faculty of Medicine, Cairo University, Cairo, Egypt. noha_afifi@windowslive.com
- Publication Type:Original Article
- Keywords:
Myelo-suppression;
Cyclophosphamide;
CD34;
CD20;
Astragalus Membranaceus
- MeSH:
Adipocytes;
Adult;
Animals;
Asian Continental Ancestry Group;
Astragalus membranaceus*;
B-Lymphocytes;
Bone Marrow;
Cyclophosphamide;
Drug Therapy*;
Humans;
Male;
Plants, Medicinal;
Rats*
- From:International Journal of Stem Cells
2014;7(1):12-22
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Myelo-suppression is the most common toxicity encountered in the oncology clinic today. This study was planned to investigate the possible protective and therapeutic role of the traditional Chinese Medicinal Herb; Astragalus Membranaceus (AM), on chemotherapy-induced myelosuppression. METHODS AND RESULTS: This study was carried out on thirty six adult male albino rats. They were divided into: Group I Control Group (n=6) received a vehicle of phosphate buffered saline (PBS) solution. Group II (n=12) were injected I.P. with cyclophosphamide (CY) for 3 days (gIIa n =6) and continued for one more week to receive AM orally (gIIb n=6). Group III (n=6) received CY I.P. together with AM orally for 3 days. Group IV (n=12) received AM orally for one week (gIVa n=6) and continued for extra three days receiving CY I.P. with AM orally (gIVb n=6). Blood samples were analysed for Total Leucocytic Count and Lymphocytic Count. Counting of CD34 +ve cells in bone marrow was performed by flowcytometry. Bone marrow sections were subjected to H&E stain as well as immunohistochemical staining for anti- CD20 antibody. The mean area % of cellular bone marrow regions occupied by developing haemopoietic cells, mean area of fat cells and mean number of CD20 immunopositive B lymphocytes in the bone marrow were measured by histomorphometric studies and statistically compared. AM proved to have a myelo-protective and myelo-therapeutic capacity, evidenced at both laboratory and morphological levels. CONCLUSIONS: The greatest myelo-potentiating effect of AM was achieved when supplied before and together with CY therapy.
